Disclosure filings show that U.S. Representative Kevin Hern sold his entire holding in the healthcare insurance giant on December 23, 2025, in a transaction valued between $250,001 and $500,000. Reported on January 22, 2026, as a full exit, the sale came after a year of significant share price volatility driven by rising medical costs, margin compression in Medicare Advantage and management upheaval. Hern—who sits on the House Ways and Means Subcommittee on Health—had built his position through 12 separate purchases between October 2021 and July 2024, only to liquidate when the position was underwater across all lots. The timing and scale of the sale have raised questions about market timing, risk management and whether policy developments influenced the decision.

Since the December transaction, shares have climbed more than 9%, outperforming major benchmarks over the same period. Retail sentiment on social platforms swung dramatically—from a bearish score of 18 in November to a peak of 82 in late December—before moderating to a neutral reading of 42 in recent weeks. Institutional validation has been bolstered by reports of a five-million-share stake held by a prominent investment conglomerate, while options market activity points to continued interest in long-dated call positions. The stock’s rally and stabilization have prompted analysts to reassess downside risks, particularly as operational headwinds in core segments show signs of easing.

The Federal Trade Commission has granted a 14-day stay in its administrative case against major pharmacy benefit managers, including the company’s prescription benefits arm, delaying evidentiary hearings until July 1, 2026. The lawsuit—filed in September 2024—accuses PBMs of practices that inflated insulin prices through rebate structures and markups. Earlier FTC reports highlighted price inflations of hundreds to thousands of percent on certain specialty generics. The pause suggests active settlement discussions with federal regulators, even as political pressure and investigative reporting intensify scrutiny of PBM profit models and their impact on drug costs.